B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

CDA

MOLECULAR TARGET

cytidine deaminase

UniProt: P32320NCBI Gene: 9782 compounds

CDA (cytidine deaminase) is targeted by 2 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting CDA

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1Tetrahydrouridine2.087
2Uridine0.691

About CDA as a Drug Target

CDA (cytidine deaminase) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 2 compounds with documented CDA interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

CDA inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.